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ABSTRACT
Rodent-based studies have shown that the membrane properties of oligodendrocytes play
prominent roles in their physiology and shift markedly during their maturation from the oligo-
dendrocyte precursor cell (OPC) stage. However, the conservation of these properties and matu-
ration processes in human oligodendrocytes remains unknown, despite their dysfunction being
implicated in human neurodegenerative diseases such as multiple sclerosis (MS) and amyotro-
phic lateral sclerosis (ALS). Here, we have deﬁned the membrane properties of human oligoden-
drocytes derived from pluripotent stem cells as they mature from the OPC stage, and have
identiﬁed strong conservation of maturation-speciﬁc physiological characteristics reported in
rodent systems. We ﬁnd that as human oligodendrocytes develop and express maturation
markers, they exhibit a progressive decrease in voltage-gated sodium and potassium channels
and a loss of tetrodotoxin-sensitive spiking activity. Concomitant with this is an increase in
inwardly rectifying potassium channel activity, as well as a characteristic switch in AMPA recep-
tor composition. All these steps mirror the developmental trajectory observed in rodent sys-
tems. Oligodendrocytes derived from mutant C9ORF72-carryng ALS patient induced pluripotent
stem cells did not exhibit impairment to maturation and maintain viability with respect to con-
trol lines despite the presence of RNA foci, suggesting that maturation defects may not be a
primary feature of this mutation. Thus, we have established that the development of human
oligodendroglia membrane properties closely resemble those found in rodent cells and have
generated a platform to enable the impact of human neurodegenerative disease-causing muta-
tions on oligodendrocyte maturation to be studied. STEM CELLS 2016;34:1040–1053
SIGNIFICANCE STATEMENT
Two main classes of cells are present in the brain - neurons and glia. Both classes can be sub-
divided further and in the case of glia these fall into two main categories - astrocytes and oli-
godendrocytes. Studies from rodents have indicated that as oligodendrocytes mature from
their precursor cells they undergo changes such that they express different types and abundan-
ces of ion channels which are multimeric protein complexes that allow ions to pass across the
cell membrane. Our study for the first time characterizes this process in human oligodendro-
cytes derived from pluripotent stem cells and serves not only to document this process in
human cells but illustrates how this can be used to study diseases associated with oligodendro-
cyte dysfunction.
INTRODUCTION
Dependent on context, it is increasingly recog-
nized that oligodendrocytes, aside from their
normal physiological function, can be injurious
or regenerative in disease states. The regener-
ative potential of oligodendrocyte precursor
cells (OPCs) is a major focus for research into
demyelinating disease. Moreover, functional
perturbations in oligodendrocyte differentia-
tion and maturation from OPCs are implicated
in disorders such as multiple sclerosis and
amyotrophic lateral sclerosis (ALS) [1, 2]. Oligo-
dendrocyte pathology ranging from inclusions
and myelin abnormalities to reactive changes
in OPCs is described in ALS [3–5].
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TISSUE-SPECIFIC STEM CELLS
Demyelination is also present in the most common genetic
cause of ALS due to a hexanucleotide intronic repeat in the
C9ORF72 gene that accounts for approximately 10%–50% of
familial and around 6%–10% of sporadic cases across Euro-
pean populations [3, 6–8]. However, the differentiation and
maturation potential of C9ORF72 repeat expansion-carrying
OPCs has not been investigated before. Improved mechanistic
understanding of the differentiation and maturation of human
oligodendrocytes from OPCs is therefore of considerable inter-
est as a point of potential therapeutic intervention. Speciﬁ-
cally the excitable membrane properties of oligodendrocytes
that are central to their physiological role have been shown
in rodent studies to markedly change upon differentiation and
maturation of the OPC to an oligodendrocyte. The necessity
to explore oligodendrocyte maturation in a human context is
underlined by evidence for both interspecies cellular and
molecular differences in neurons and astrocytes [9–13] as
well as speciﬁc differences in the spatial distribution and
development of rodent and human oligodendrocytes [14].
However, the conservation of excitable membrane properties
throughout the maturation process in human oligodendro-
cytes remains unknown, despite their dysfunction being impli-
cated in diseases such as ALS. The ability to derive
oligodendrocyte lineage cells from human pluripotent stem
cells (hPSCs) including from patients carrying disease causing
mutations provides an opportunity to investigate the matura-
tion and electrophysiological properties of human oligoden-
drocytes in both normal physiological and disease contexts
[15–17].
Here, we have designed a protocol that reliably generates
a scalable population of OPCs from hPSCs that upon differen-
tiation yields cultures enriched for oligodendrocytes, enabling
us to study the maturation and physiological properties of oli-
godendrocytes. Using a combination of electrophysiological,
biochemical, and immunohistochemical approaches, we show
species conservation of the deﬁning physiological properties
of differentiated oligodendrocytes that are distinct from those
of OPCs. OPCs derived from mutant C9ORF72-carrying ALS
patient induced pluripotent stem cells (iPSCs) did not exhibit
impairment to maturation or differences in viability despite
the presence of key pathological features, including RNA foci,
suggesting that maturation defects may not be a primary fea-
ture of this mutation.
MATERIAL AND METHODS
OPC and Oligodendrocyte Production
The SHEF4 line (male, UK Stem Cell Bank), referred to as the
“ES line”, was obtained under full Ethical/Institutional Review
Board approval of the University of Edinburgh. Written
informed consent was obtained from each participant providing
the lines iPS1 (female), iPS2 (male), iPSC91 (female), and iPSC92
(male). The derivation, characterization, and validation of iPS
lines were performed as described previously [18] and are
detailed in the Supporting Information Text. For neuralization,
spontaneous embryo body formation was induced following
cell lifting with dispase (17105-041, Life Technologies, CA, USA)
and collagenase (17104-019, Life Technologies). Embryo bodies
were cultured for 7 days, with dual-SMAD inhibition [19], and
in chemically deﬁned media (CDM) that contained 50% Iscove’s
modiﬁed Dulbecco’s medium (Invitrogen, CA, USA, 50% F12,
BSA (5mg/ml, Europa, Cambridge, UK), 1% chemically deﬁned
Lipid 100 (Invitrogen), monothioglycerol (450 lM, Sigma-
Aldrich, Gillingham, UK), insulin (7mg/ml), Roche, Basel, Swit-
zerland), transferrin (15mg/ml, Roche), 1% penicillin/strepto-
mycin), supplemented with N-acetyl cysteine (1mM, Sigma),
activin Inhibitor (10lM, R&D Systems, MN, USA), and Dorso-
morphin (2 lM, Merck Millipore, Darmstadt, Germany). NPCs
were cultured in suspension as neurospheres with media
changes every 2–3 days. Neurospheres were then caudalized by
the addition of retinoic acid (1 lM, Sigma) for a further 7 days.
At this stage, neuropheres were quality controlled for their
morphology and the formation neural rosettes before subse-
quently being ventralized with the addition of the sonic hedge-
hog agonist purmorphamine (1 lM, Calbiochem, CA, USA) for 7
days in Advanced DMEM/F12 (Invitrogen) containing: 1% N-2
supplement (Invitrogen), 1% B27 supplement (Invitrogen), 1%
penicillin/streptomycin (Invitrogen), 0.5% GlutaMAX (Invitro-
gen), and 5 lg/ml heparin (Sigma). Ventral spinal cord pat-
terned progenitor cells were then further expanded in the
presence of basic ﬁbroblast growth factor (FGF)-2 (10 ng/ml,
PeproTech, NJ, USA) for 7 days. Subsequently, neuronal and glia
differentiation of NPCs was triggered by FGF2 withdrawal for a
further 2 weeks. At this stage neurospheres-containing OLIG21
cells were further expanded for additional 2 weeks in the pres-
ence of FGF2 (10 ng/ml), PDGFa (Platelet-derived growth factor
alpha, 20 ng/ml, PeproTech), purmorphamine (1lM), and SAG
(1 lM, Calbiochem), IGF-1 (10 ng/ml, PeproTech), T3 (60 ng/ml,
Sigma), and 13 ITS (Gibco, NY, USA) before initiating oligoden-
drocyte differentiation. It was possible to maintain OPC-
containing spheres in this media for up to 8 weeks. Terminal dif-
ferentiation of oligodendrocytes was achieved by mitogen with-
drawal (except for T3 and IGF-1) following single-cell
dissociation using papain (Worthington Biochemical, NJ, USA)
and plating on Matrigel (SLS, 354230; 1 in 100 dilution), ﬁbro-
nectin (20 lg/ml, F2006, Sigma-Aldrich), laminin (10lg/ml,
L2020, Sigma-Aldrich) coated coverslips (or plates) at a density
of 20,000-30,000 cells per 0.3 cm2. For biochemical studies, cul-
tures were dissociated with accutase (Life technologies), and
separation of O41-oligodendrocytes was achieved by magnetic-
activated cell sorting (MACS) using anti-O4 MicroBeads (MACS
130-096-670) and MACS LS columns (MACS 130-042-401) fol-
lowing the manufacturer’s instructions.
Immunocytochemistry
All steps were performed at 18–248C. Cells were ﬁxed with
4% paraformaldehyde in phosphate-buffered saline (PBS) for
20 minutes, permeabilized with 0.2% Triton X-100 containing
PBS, then blocked in 3% goat serum, then incubated with
appropriate primary and secondary antibodies. Nuclei were
counterstained with either DAPI (40,6-diamidino-2-phenylin-
dole, Sigma-Aldrich) or Hoechst staining (bisbenzimide;
Sigma), and coverslips were mounted on slides with FluorSave
(Merck, NJ, USA). Fluorescent imaging was performed using
an Axioscope (Zeiss, Oberkochen, Germany) microscope.
Images were processed with Axiovision V 4.8.1 (Zeiss).
Regions of interest were selected based on uniform DAPI
staining and imaged for two to four ﬂuorescent channels, and
immunolabeled cells counted manually with ImageJ64 (v 1.47)
software for an area of 162.40 lm2. Positive staining was
deﬁned as a signal clearly above the background ﬂuorescence
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present in areas devoid of cells. At least three independent
images per culture and at least three independent cultures
from three independent conversions were analyzed.
Live-staining was performed with the addition of 150ll of
O4 antibody (1:300, R&D Systems) or platelet-derived growth
factor alpha (PDGFRa) (1:200 Cell Signaling, MA, USA) in cul-
ture media to 100ll of culture media left in each 24-well
plate. Cells were incubated at 378C for 40 minutes after which
coverslips were washed with media and stained with second-
ary antibody diluted in media (1:1,000). Cells were incubated
at 378C for a further 30 minutes, washed, and then assessed
electrophysiologically.
Electrophysiology
The whole-cell patch conﬁguration was used to record macro-
scopic currents as described previously [20, 21]. Reported
potential values are corrected for liquid junction potential
(114 mV). Responses to a-amino-3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA)
were recorded at –74 mV and responses to gamma-aminobu-
tyric acid (GABA) and glycine at –14 mV. Current and voltage
measurements were typically low-pass ﬁltered online at 2
kHz, digitized at 10 kHz, and recorded to computer using the
WinEDR V2 7.6 Electrophysiology Data Recorder (J. Dempster,
Department of Physiology and Pharmacology, University of
Strathclyde, UK; www.strath.ac.uk/Departments/PhysPharm/).
Statistical Analysis
Data are presented as mean6 SEM. Rectiﬁcation indices (RI)
were calculated from the following equation:
RI5
½I=ð162EREVÞ
½I=ð21242EREVÞ
where I represents current amplitude and EREV indicates the
reversal potential of currents. The number of experimental
replicates is denoted as “n” while “N” represents number of
de novo preparations from which n is obtained. The Shapiro-
Wilk test was used to assess whether data were normally dis-
tributed and then either a Student’s t test or a Mann Whitney
U test were used to determine statistical signiﬁcance with *,
p< 0.05; **, p< 0.01; and ***, p< 0.001.
Details of EdU labeling and detection, ﬂow cytometry,
quantitative polymerase chain reaction (qPCR), and RNA ﬂuo-
rescence in situ hybridization (FISH) methodologies are
included in the Supporting Information Text.
RESULTS
Derivation of OPCs and Oligodendrocytes from Control
hPSCs
We ﬁrst optimized a protocol to generate enriched in vitro cul-
tures of control oligodendrocytes from three hPSC lines; one
embryonic stem cell (ESC) line and two iPSCs (iPS1, iPS2; sum-
marized in Fig. 1A). In brief, expansion of OLIG21 retinoic acid-
and purmorphamine-treated NPCs [18] in the presence of FGF
and PDGF resulted in conversion into OPCs that were positive
for PDGFRa [22] over 2–4 weeks. Plate-down and withdrawal of
mitogens resulted in oligodendrocyte differentiation. Quantita-
tive immunocytochemistry performed 1 week after differentia-
tion (Fig. 1B–1D) revealed that cultures gave rise to a majority of
O41-labeled oligodendendrocytes (ESC, 65.06 2.4%; iPS1,
68.56 6.8%; iPS2, 70.56 10.8%) with a residual population of
PDGFRa1-OPCs (ESC, 10.56 1.1%; iPS1, 11.66 0.9%; iPS2,
20.36 1.1%). Notably, O41-oligodendrocytes exhibited high
coexpression of myelin basic protein (MBP) (ESC, 86.56 6.1%;
iPS1, 87.26 3.9%; iPS2, 92.76 3.3%) and very little overlapping
PDGFRa expression (ESC, 6.16 2.7%; iPS1, 7.26 4.5%; iPS2,
5.46 2.6%; Fig. 1E, 1F). By week 3 of differentiation, the num-
ber of O41 cells remained at levels similar to those seen at
week 1 across all lines (p 0.3, unpaired t tests). PDGFRa1-
OPCs and O41/MBP1-oligodendrocytes displayed distinct mor-
phology, with OPCs being morphologically less complex whereas
oligodendrocytes possessed a radial and multibranched mor-
phology (Fig. 1F). Sholl analysis also revealed an increase in
number and complexity of O41/MBP1 oligodendrocyte proc-
esses from week 1 to 3 (Fig. 1G).
Maturation of hPSC-Derived Oligodendrocyte-Lineage
Membrane Currents
To address whether human OPCs and oligodendrocytes exhibit
conservation of cell-type speciﬁc membrane conductances in
response to membrane depolarization [23–25], we undertook
electrophysiological recordings from OPCs and cells colabeled
for O4 and MBP. Having already established extremely limited
colabeling of PDGFRa and O4 (Fig. 1C, 1E), electrophysiological
recordings were undertaken on live-stained OPCs and differenti-
ated oligodendrocytes using antibodies against PDGFRa and O4
(Fig. 2A). For PDGFRa1-OPCs at week 1, a depolarizing voltage-
step protocol induced large outward currents that consisted of
transient and sustained components (Fig. 2A). In contrast, the
application of the same voltage-step protocol applied to O41-
oligodendrocytes at week 1 and 3 yielded currents that were
substantially lower in amplitude than those observed in OPCs
(Fig. 2A). Mean current–voltage (I–V) relationships constructed
from this data show that evoked membrane currents in hPSC-
derived OPCs are outwardly rectifying and differentiation to
O41-oligodendrocytes is associated with a reduced degree of
outward rectiﬁcation (Fig. 2B). Rectiﬁcation indices were subse-
quently calculated (see Materials and Methods section) to
quantify such rectiﬁcation shifts and revealed that current recti-
ﬁcation was reduced in each line of week 3 O41-oligodendro-
cytes when compared with the levels seen in PDGFRa1-OPCs
(ESC, 13.46 2.2%; iPS1, 11.86 3.8%; iPS2, 12.66 2.5%, Fig.
2C). A reduction in input resistance also accompanies this shift
in membrane current properties (Fig. 2D) therefore providing
added support to the notion that changes in ion channel
expression accompany oligodendrocyte differentiation from
hPSC-derived OPCs. Furthermore, whole-cell capacitance meas-
urements are consistent that the membrane compartment
increases in size during the oligogodendrocyte differentiation
process (Fig. 2E). Together these data indicate that maturation
is active in differentiated oligodendrocytes.
Distinctive Maturation-Specific Changes in Functional
Ion Channel Expression in hPSC-Derived
Oligodendrocyte-Lineage Cells
Rodent OPCs and oligodendrocytes exhibit cell-type speciﬁc
voltage-gated ion channel expression proﬁles, which are corre-
lated to developmentally deﬁned oligodendroglial immunohisto-
chemical markers and underpin the properties of the membrane
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currents described above [24, 25]. Depolarizing current injec-
tions applied to PDGFRa1-OPCs gave rise to tetrodotoxin (TTX,
300 nM) sensitive spikes (16 from 18 cells) and indicate the func-
tional expression of voltage-gated Na1 (NaV) channels (Fig. 3A).
As has been reported for rodent OPCs [26] spiking behavior did
not ﬁt the criteria that would be used to classify neuronal action
Figure 1. Derivation and speciﬁcation of oligodendrocytes from human pluripotent stem cell (hPSC)-derived oligodendrocyte precursor
cells (OPCs). (A): Summary of the protocol used to generate hPSC-derived oligodendrocytes: (1) hPSCs were neuralized via dual-SMAD
inhibition. (2) NPCs were patterned to ventral spinal cord by exposure to retinoic acid and sonic hedgehog agonists, purmorphamine,
and SAG. (3) spinal cord-patterned NPCs were converted to OPCs by exposure to PDGFa and other mitogens. (4) OPCs could be further
expanded by mechanical dissociation. (5) Oligodendrocyte differentiation was induced by mitogen withdrawal. (B): Representative stain-
ing of cells 1 week post-mitogen removal identiﬁes OLIG21-progenitors, and cells expressing PDGFRa, O4, and MBP in all lines exam-
ined. Scale bar5 50lm. (C): Percentage of PDGFRa1-cells (ES/iPS1/iPS2: N5 4/4/3) and (D) O41-cells (ES/iPS1/iPS2: N5 4/13/13) in
week 1 cultures. (E): Percentage O41-cells that express PDGFRa(ES/iPS1/iPS2: N5 4/4/3) and MBP (ES/iPS1/iPS2: N5 4/5/6). Equivalent
cellular speciﬁcation was observed across all lines. (F): Example images illustrating no overlap of PDGFRa1- and O41-cells (upper panels)
but substantial overlap of MBP1- and O41-cells (lower panels). Scale bar5 12 lm. (G): Sholl analysis performed upon week 1 and 3
O41-oligodendrocytes. Abbreviations: DAPI, 4’,6-diamidino-2-phenylindole; ES, embryonic stem cell; FGF, ﬁbroblast growth factor; hPSC,
human pluripotent stem cell; IGF, Insulin-like growth factor; iPS, induced pluripotent stem cell; MBP, myelin basic protein; NPC, neural
precursor cell; OL, oligodendrocyte; OPC, oligodendrocyte precursor cell; PDGF, platelet-derived growth factor; RA, retinoic acid; SAG,
smoothened agonist; scNPC, spinal cord-patterned neural precursor.
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potential ﬁring as these spike amplitudes did not generally cross
0 mV. The existence of native spiking and non-spiking OPC popu-
lations has been subject of numerous recent studies [26–28],
and we therefore further isolated and characterized the NaV-
channels expressed in hPSC-oligodendroglial cells using a depo-
larizing voltage-step protocol (Fig. 3B, 3C). We found 89% of
ESC- and 100% of iPSC-derived PDGFRa1-OPCs possessed TTX-
sensitive currents. However, all functional TTX-sensitive NaV-
channel expression (current density) is lost in week 3 O41-oligo-
dendrocytes derived from the ES line (Fig. 3D) and iPS lines
(data not shown).
In rodent OPCs delayed outwardly rectifying K1 (IK) chan-
nels and A-type K1 (IA) channels largely contribute to sus-
tained and transient outward membrane currents,
respectively, and are downregulated upon differentiation to
oligodendrocytes [24, 25]. Analysis of the expression of IK-
mediated currents (Fig. 4A, 4B) in OPCs and oligodendrocytes
derived from the ES line revealed that there was a greater
than 50-fold reduction in IK-channel current density in week 3
O41-oligodendrocytes compared with the levels seen in week
1 PDGFRa1-OPCs (Fig. 4C). IA-channel activity (Fig. 4D, 4E)
was also reduced as cells differentiated from PDGFRa1-OPCs
to O41-oligodendrocytes (Fig. 4F). This strong downregulation
in week 3 O41-oligodendrocytes of IK (1.96 0.8% of the
value seen in week 1 PDGFRa1-OPCs) and IA (7.66 1.9%)
seen in the ES line was recapitulated in the two iPS lines (For
IK; iPS1, 2.96 1.2%, iPS2, 7.06 1.1%, n5 4–6, N5 2, and for
IA; iPS1, 0.86 0.4%, iPS2, 5.06 0.5%, n5 3–9, N5 2–9,
p<0.001 in all cases, Mann-Whitney U tests). IA and IK cur-
rents were detected in all PDGFRa1-OPCs. In ESC-derived
week 3 O41-oligodendrocytes expression of IA and IK currents
were observed in 78% and 83% of cells, respectively, whereas
in iPSC-derived week 3 O41-oligodendrocytes IA and IK cur-
rents were seen in 83% and 67% of cells, respectively.
In contrast to decreases in IK- and IA-channel expression, dif-
ferentiation of rodent oligodendrocytes from OPCs is associated
with an increase in inwardly rectifying K1 (Kir) channel expres-
sion [24]. Speciﬁcally the Kir4.1 subunit has been reported to
Figure 2. Membrane current properties of human pluripotent stem cell-derived oligodendrocyte precursor cells (OPCs) and oligoden-
drocytes. (A): Whole-cell current recordings from a PDGFRa1-OPC (blue) and week 3 O41-oligodendrocyte (orange) in response to a
voltage-step protocol that involved incremental application of 20 mV voltage steps from a holding potential of –84 mV. Live-stained cells
are shown inset. (B): Mean normalized current–voltage plots for PDGFRa1-OPCs, week 1 (circles) and week 3 (triangles) O41-oligoden-
drocytes (n5 9–17, N5 3–6) derived from the ES line. Current amplitudes were measured 175 milliseconds after voltage-step initiation
and normalized to –64 mV current data. (C): Mean PDGFRa1-OPC (iPS1/iPS2: n5 10/5, N5 3/1) and week 3 O41-oligodendrocyte
(iPS1/iPS2: n5 8/6, N5 4/2) rectiﬁcation index data calculated for each line examined. (D): Mean input resistance measurements for
PDGFRa1-OPCs (ES/iPS1/iPS2: n5 20/21/8, N5 3/3/3) and O41-oligodendrocytes (ES/iPS1/iPS2: n5 26-32/19/7, N5 3/3/3). (E): Mean
whole-cell capacitance measurements for PDGFRa1-OPCs (ES/iPS1/iPS2: n5 22/21/12, N5 3/3/3) and O41-oligodendrocytes (ES/iPS1/
iPS2: n5 32-41/26/7, N5 3/3/3). *, p< 0.05; **, p< 0.01, ***, p< 0.001, respectively. Abbreviations: ES, embryonic stem cell; iPS,
induced pluripotent stem cell; PDGFRa, platelet-derived growth factor receptor alpha.
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play a pivotal role in oligodendrocyte development, myelination
and setting the resting membrane potential (RMP) of native
mature oligodendrocytes [29] but see [30]. There are no selec-
tive blockers that can be used to isolate pharmacologically
Kir4.1-mediated currents and therefore we conﬁrmed immuno-
histochemically the presence of Kir4.1 subunits in O4
1/MBP1-
oligodendrocytes and PDGFRa1-OPCs (Fig. 5A). Subsequent
analysis of Kir channel expression in the ES-line (Fig. 5B, 5C)
indicated an increase in inwardly rectifying current densities in
week 3 oligodendrocytes compared with both week 1 oligoden-
drocytes and PDGFRa1-OPCs (Fig. 5D). This was also accompa-
nied by an increase in the detection of Kir currents (56% in
PDGFRa1-OPCs and 100% in week 3 O41-oligodendrocytes).
Associated with this, we observed a hyperpolarization of the
RMP from –39.26 0.4 mV in OPCs to –53.56 1.0 mV in week 3
oligodendrocytes (Fig. 5E). Thus, the maturation of human oli-
godendrocytes displays a comparable proﬁle of potassium chan-
nel conductances to that seen in rodents.
Expression of Neurotransmitter Ligand-Gated Ion
Channels in hPSC-Derived Oligodendroglial Cells
Ligand-gated ion channels (LGICs) for a variety of neurotrans-
mitters play major roles in oligodendroglial-lineage cell physiol-
ogy and pathophysiology [31] and we therefore examined the
functional expression of AMPARs, GABAARs, NMDARs, and
strychnine-sensitive glycine receptors (GlyRs) in our cultures.
Application of AMPA (10lM) elicited small inward currents in
PDGFRa1-OPCs which could be potentiated (1,3206 500%;
n5 5) in the presence of the AMPAR selective potentiator, cyclo-
thiazide (10lM; Fig. 6A). The AMPAR antagonist 6-cyano-7-nitro-
quinoxaline-2,3-dione (CNQX) (30lM) blocked these agonist-
evoked currents. All cells examined responded to AMPA,
although AMPAR current densities decreased as OPCs matured
to oligodendrocytes (Fig. 6C). Responses to NMDA (100lM, in
the presence of glycine (50lM)) were not observed in either
PDGFRa1-OPCs (n5 6) or week 3 O41-oligodendrocytes (n5 8;
Fig. 6B, 6C). GABA (100lM) evoked responses in 63% in
PDGFRa1-OPCs (n5 8) and 74% in O41-oligodendrocytes
(n5 19) which were blocked by picrotoxin. GABAAR current den-
sities decreased during OPC maturation (Fig. 6B, 6C). Applica-
tions of glycine (100lM) did not elicit responses in PDGFRa1-
OPCs or week 3 O41-oligodendrocytes (data not shown).
Expression of Arginine-Edited GluA2 AMPAR Subunits
Is Upregulated in hPSC-Derived Oligodendrocytes
The expression and activation of OPC AMPARs is considered
crucial to OPC physiology and has been implicated in oligo-
dendrocyte pathologies [32–34]. We further explored the
Figure 3. Voltage-gated Na1-channel expression in human pluripotent stem cell-derived oligodendrocyte precursor cells (OPCs) and oligo-
dendrocytes. (A): Current-clamp recording demonstrating that PDGFRa1-OPCs exhibited tetrodotoxin (TTX)-sensitive spikes in response to
depolarization by current injection (each current step below trace represents 10 pA). (B): To isolate and measure NaV-channel activity, the
membrane potential was initially stepped in 20 mV increments from –84 mV to1 16 mV (activation). Scale bars5 500 pA, 5 milliseconds.
The protocol was then repeated in the presence of TTX and the current data subtracted from that of the former to yield the TTX-sensitive
NaV-speciﬁc current. Not all TTX-sensitive currents are shown for ﬁgure clarity. (C): Normalized current–voltage plot of NaV-channel activity
expressed by PDGFRa1-OPCs. Data were normalized to 116 mV current data. (D): Decrease in NaV-channel expression from PDGFRa
1-
OPCs to O41-oligodendrocytes (n5 5–18, N5 3; Mann Whitney U tests). ***, p< 0.001. Abbreviations: PDGFRa, platelet-derived growth
factor receptor alpha; TTX, tetrodotoxin.
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AMPAR properties in hPSC-derived oligodendroglial cells.
Quantiﬁcation of AMPAR subunit mRNA expression by quanti-
tative real-time PCR (qRT-PCR) revealed that there was an
increase in the GluA2, GluA3, and GluA4 mRNA expression
levels relative to GluA1 in week 3 O41-oligodendrocytes com-
pared with the levels observed in OPCs cultures in which OL
differentiation was inhibited by absence of mitogen with-
drawal (Fig. 6D). Our data indicate that GluA2 is the most
prominently expressed AMPAR subunit in week 3 O41-
oligodendrocytes.
GluA2 subunits are predominantly RNA edited in approxi-
mately 99% of central nervous system mRNA transcripts,
where editing results in an arginine codon replacing a gluta-
mine codon in the M2 re-entrant loop region of the ion chan-
nel. The presence of the edited GluA2 [GluA2(R)] subunit in
AMPAR complexes imparts low single-channel conductance,
low Ca21 permeability, and insensitivity to polyamine-
mediated channel block [35]. We examined the composition
of AMPARs expressed by hPSC-derived OPCs and oligodendro-
cytes by estimating the mean unitary single-channel conduct-
ance using nonstationary ﬂuctuation analysis (Fig. 6E, 6F [21]).
Unitary conductances were estimated by plotting current-
variance plots from AC- and DC-coupled recordings of currents
elicited by AMPA (10lM) in the presence of cyclothiazide
(10 lM) or in some recordings, AMPA (100 lM) alone (Fig.
6G). For the ES line, the mean AMPAR conductance of
PDGFRa1-OPCs decreased from 8.06 0.2 pS (n5 14, N5 4)
to 2.96 0.1 pS in week 3 O41-oligodendrocytes (n5 4, N5 2,
p<0.001, unpaired t tests, Fig. 6H). Equivalent data were also
obtained from iPSC-derived oligodendrocyte-lineage cells (Fig.
Figure 4. Voltage-gated K1-channel expression in human pluripotent stem cell-derived oligodendroglia. (A): To isolate Ik-channel activ-
ity, 10 mV incremental voltage-pulses were initially applied to activate Ik-channels in the presence of tetrodotoxin (TTX) (activation). This
was then repeated in the presence of TEA and the current data subtracted from that of the former to determine the IK-speciﬁc current
(subtracted). IK-current amplitudes were measured 200 milliseconds after activation. The examples shown are from PDGFRa
1-oligoden-
drocyte precursor cells (OPCs). (B): Normalized current–voltage plot of IK-channel activity measured from PDGFRa
1-OPCs (n5 4) and
O41-oligodendrocytes (n5 4). Data were normalized to 146 mV current data. (C): Decrease in IK-channel expression from PDGFRa
1-
OPCs to O41-oligodendrocytes (n5 8–15, N5 3-4). Current amplitude data were measured from the 100-mV step. (D): IA-channel activ-
ity was measured in the presence of TTX and Cd21 (100lM). The holding potential was pre-stepped to –124 mV (500 milliseconds) and,
there from, the holding potential depolarized in 10 mV increments before returning to –84 mV (activation). Since IA-channels inactivate
rapidly upon depolarization, an inactivation protocol pre-stepped cells to –34 mV from –84 mV to isolate non-IA current (inactivation),
which was subtracted from the former to generate the IA-mediated current (subtracted). IA-current amplitudes were measured from the
transient peak responses. The examples shown are from PDGFRa1-OPCs. (E): Normalized current–voltage plot of IA-channel activity
measured from PDGFRa1-OPCs (n5 6) and O41-oligodendrocytes (n5 4). Data were normalized to 136 mV current data. (F): Decrease
in IA-channel expression from PDGFRa
1-OPCs to O41-oligodendrocytes (n5 6-12, N5 3-4). Current amplitude data were measured from
the depolarization step to 116 mV. *, p< 0.05; ***, p< 0.001. Abbreviations: PDGFRa, platelet-derived growth factor receptor alpha;
TEA, tetraethyl ammonium.
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6H). The data are consistent with the notion that GluR2(R)
subunits are functionally upregulated in AMPARs expressed by
oligodendrocytes. Supporting the idea that OPCs express a
greater proportion of AMPARs that lack edited GluA2 subunits
and oligodendrocytes AMPARs contain edited GluA2 subunits
is the fact that the GluA2(R)-lacking AMPAR antagonist poly-
amine, 1-naphthyl acetyl spermine (NASPM, [36]) caused sub-
stantial inhibition of AMPAR-mediated currents in PDGFRa1-
OPCs (Fig. 6I), but not week 3 O41-oligodendrocytes (Fig. 6J,
6K).
Oligodendrocytes Derived from Mutant C9ORF72
Patients Express Intranuclear RNA Foci, but do not
Exhibit Impairment in Maturation
Having established benchmark physiological and maturation
features of control OPCs and to assess the maturation proﬁle
of oligodendrocytes in a disease model we next derived oligo-
dendroglia from hPSCs obtained from two ALS patients
(iPSC91 and iPSC92) harboring mutations in the C9ORF72 gene
(Fig. 7A). Mutations in the C9ORF72 gene are the most com-
mon manifestation of familial ALS and contribute to 10% of
sporadic cases [37, 38].
The iPSC9 lines were previously determined to contain the
50-GGGGCC-30 hexanucleotide repeat expansions [39]. We
found the efﬁciency of oligodendrocyte-lineage speciﬁcation
and differentiation from mutant lines comparable with control
lines in respect to generation of enriched numbers of O41-
labeled cells (p> 0.15), which exhibit high coexpression of
MBP (p> 0.91) and little overlapping PDGFRa labeling
(p> 0.82) versus control iPS lines (Supporting Information Fig.
1A, 1B). Similarly, few PDGFRa1-OPCs persist in 3-week old
differentiation cultures versus control cells (p> 0.29; Support-
ing Information Fig. 1C).
Increased OPC proliferation has been observed in a mouse
model of ALS expressing human mutant SOD1 and appears
prevalent in ALS patient post mortem samples [3, 5]. We,
therefore, examined whether control and C9ORF72 patient-
derived OPCs differed in their rates of proliferation using
Figure 5. Inwardly rectifying K1-channel expression in human pluripotent stem cell-derived oligodendrocyte precursor cells (OPCs) and
oligodendrocytes. (A): Representative images of Kir4.1 subunit immunostaining in PDGFRa
1-OPCs (arrowhead), and O41- (arrow) and
MBP1-oligodendrocytes. Scale bar5 30lm. (B): Kir-channel measurements were performed using an extracellular solution in which KCl
(50mM) replaced an equimolar amount of NaCl. To isolate of Kir-channel activity initially 10 mV incremental voltage-steps were applied
in the range –134 mV to1 6 mV from a holding potential of –74 mV and then repeated in the presence of Ba21 (1mM). Note that
only selected voltage-step current recordings are shown in the ﬁgure for clarity. Leak-subtraction of Kir-channel current data were per-
formed using the pre-pulse current amplitude in the presence of Ba21 as zero current. It was not possible to extract a current–voltage
(I-V) plot from PDGFRa1-cells given the very low Kir channel current amplitudes. Scale bars5 100 pA, 50 milliseconds. (C): Normalized I-
V of Kir-channel activity obtained from O4
1-oligodendrocytes (n5 7). Data were normalized to –114 mV current data. (D): An increase
in mean Kir-channel expression in week 3 O4
1-oligodendrocytes (n5 8, N5 3) from that of week 1 O41-oligodendrocytes (n5 10,
N5 2) and PDGFRa1-OPCs (n5 9, N5 3). Current amplitude data were measured from the depolarization step to –134 mV. Note that
the increase in current density also factors the whole-cell capacitance. (E): The mean resting membrane potential PDGFRa1-OPCs
(n5 19, N5 3), week 1 O41-oligodendrocytes (n5 29, N5 7) and week 3 O41-oligodendrocytes (n5 20, N5 4). Error bars are
obscured by the mean data point. *, p< 0.05; **, p< 0.01, respectively. Abbreviations: PDGFRa, platelet-derived growth factor receptor
alpha; RMP, resting membrane potential.
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Figure 6. AMPA receptors in human pluripotent stem cell (hPSC)-derived oligodendrocyte precursor cells (OPCs) and oligodendrocytes.
(A): AMPA-mediated whole-cell current responses in a PDGFRa1-OPC are strongly potentiated by cyclothiazide and blocked by CNQX.
(B): Depicts sample recordings in which responses to applications of GABA (100lM), NMDA (100lM, in the presence of glycine
[50lM]) were obtained from week 3 O41-oligodendrocytes. (C): Mean current densities for AMPA (n5 10/7/11, N5 2/1/2), NMDA
(n5 6/8, N5 2/2), and GABA responses (n5 8/19, N5 3/3). (D): Mean normalized mRNA fold expression data for AMPAR subunits
GluA1-GluA4 in OPC cultures (N5 3) and week 3 O41-oligodendrocytes (N5 13) as assessed by quantitative real-time polymerase chain
reaction. Data were normalized to GluA1 for each maturation stage after normalizing to b-actin and GAPDH. (E): Sample nonstationary
ﬂuctuation analysis recordings of AMPAR-mediated currents from a PDGFRa1-OPC and, (F) week 3 O41-oligodendrocyte. (G): Plot
describing the linear relationship of the variance of the AC-coupled current to the DC-current amplitude for the former recordings in c
and d. The ﬁtted slopes for each plot gave respective unitary single-channel current amplitude estimates of 20.45 pA and 20.1 pA,
respectively, from which the unitary conductance was calculated. (H): Mean AMPAR conductance for PDGFRa1-OPCs and O41-oligoden-
drocytes derived from control hPSC lines. (I): Example recording of 1-naphthyl acetyl spermine (NASPM) block of steady-state currents
evoked by AMPA in a PDGFRa1-OPC and, (J) week 3 O41-oligodendrocyte. (K): Mean percentage block of AMPA currents by NASPM. *,
p< 0.05; **, p< 0.01; ***, p< 0.001, respectively. Abbreviations: AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CNQX,
6-cyano-7-nitroquinoxaline-2,3-dione; CTZ, cyclothiazide; GABA, gamma-aminobutyric acid; NASPM, 1-naphthyl acetyl spermine; NMDA,
N-methyl-D-aspartate; PDGFRa, platelet-derived growth factor receptor alpha.
Figure 7. Oligodendrocytes derived from mutant C9ORF72 patients. (A): Representative staining of iPSC91 and iPSC92 cells 1 week post-
mitogen removal identiﬁes OLIG21-progenitors, and cells expressing PDGFRa, O4, and MBP. Scale bar5 50lm. (B): MACS-sorted week 3
C9ORF72 mutant (iPSC91 and iPSC92) oligodendrocytes display comparable C9ORF72-v2 and C9ORF72-total (v1, v2, and v3 isoforms)
expression compared with controls (iPS1 and iPS2) as showed by quantitative real-time polymerase chain reaction (qRT-PCR) (N5 5 for
each line, unpaired t tests). (C): Fluorescence in situ hybridization showing the presence of nuclear GGGGCC RNA-containing foci in both
iPSC91 (N5 3) and iPSC92 (N5 3) O41-oligodendrocytes. Scale bar5 10lm. (D): Percentage O41-oligodendrocytes derived from the
iPSC91 and iPSC92 lines that express nuclear GGGGCC RNA-containing foci at week 1 (iPSC91/iPSC92: N5 3/3) and 3 (iPSC91/iPSC92: N5
3/3). (E): Flow cytometry quantiﬁcation of O41 and caspase3-71 cells showing no differences in cell death across the mutant (iPSC91
and iPSC92) and control (iPS1 and iPS2) lines in basal conditions (N5 3 for each line, unpaired t tests). (F): MACS-sorted week 3
C9ORF72 mutant (iPSC91 and iPSC92) oligodendrocytes display no differences in MCT1 expression compared with controls (iPS1 and
iPS2) as showed by qRT-PCR (N5 5 for each line, unpaired t tests). (G): Mean percentage reduction in rectiﬁcation indices of currents
recorded from week 3 O41-oligodendrocytes with respect to oligodendrocyte precursor cells (OPCs) (unpaired t tests). (H): Mean
AMPAR conductance for PDGFRa1-OPCs (iPSC91/iPSC92: n5 12/11, N5 3/3) and O41-oligodendrocytes (iPSC91/iPSC92: n5 4/5, N5 2/1)
derived from the iPSC9 lines. *, p< 0.05; ***, p< 0.001, respectively. Abbreviations: DAPI, 4’,6-diamidino-2-phenylindole; iPS, induced
pluripotent stem cell; MBP, myelin basic protein; PDGFRa, platelet-derived growth factor receptor alpha.
proliferative markers EdU and Ki67. Analysis of PDGFRa1/
EdU1 and PDGFRa1/EdU1/Ki671 however showed no consist-
ent difference between control and patient-derived lines (Sup-
porting Information Fig. 1D).
We next investigated the consequence of C9ORF72 muta-
tion on differentiating oligodendrocytes. C9ORF72 hexanucleo-
tide repeat expansion results in reduction of C9ORF72
expression in the brain of patients carrying this mutation [37,
40–42]. Therefore, we examined the expression of the
C9ORF72 v2 isoform transcript, the most abundant of the iso-
forms, and total transcript levels (including isoforms v1, v2,
and v3) in mutant oligodendrocytes. We observed no consist-
ent reduction when compared with controls (Fig. 7B). The
source of variability in these data may be that the detected
C9ORF72 mRNA levels in oligodendrocytes were low when
compared with iPSC-derived neurons (relative fold expression
with respect to neurons; v1, 11.0%; v2, 41.7%; v3, 3.9%), in
agreement with the ﬁnding that C9ORF72 is highly expressed
in neurons compared with glia cells [43]. Expanded repeats
also generate repeat RNA that results in formation of RNA
foci, characteristic of C9ORF72 pathology [37, 44–46]. Using
FISH, we observed that iPSC9-derived O41-oligodendrocytes
contain nuclear RNA foci (Fig. 7C, 7D). Foci were not observed
in control O41-oligodendrocytes. In contrast we did not iden-
tify dipeptide repeat (DPR) proteins generated by non-ATG
translation of repeat RNA nor did we observe differences in
TDP-43 or p62 subcellular localization in C9ORF72 O41-oligo-
dendrocytes (data not shown). In view of recent ﬁndings sug-
gesting morphological abnormalities in differentiating
oligodendrocytes in mSOD1 experimental and pathological
studies [3], we undertook Sholl analysis of week 1 oligoden-
drocytes, but this did not reveal any difference (data not
shown). We address whether the mutation resulted in a cell
viability phenotype by undertaking quantitative caspase3/7
counts in O41-cells using FACS and no difference was found
between mutant and control (p> 0.38; Fig. 7E). Finally, noting
that the oligodendrocyte-speciﬁc lactate transporter monocar-
boxylate transporter-1 (MCT1) has been described previously
to be downregulated in post-mortem samples of ALS patients
and an ALS mouse model [3–5]. Comparisons of MCT1 mRNA
expression by qPCR in C9ORF72 mutants with control week 3
oligodendrocytes also did not reveal a difference (p> 0.22,
Fig. 7F).
Given that the presence of RNA foci in C9ORF72 patient-
derived motorneurons is associated with changes in excitabil-
ity [47] and maturation of mutant SOD1 oligodendrocytes is
severely impaired in mouse [3], we next tested whether func-
tional maturation of PSC-derived oligodendrocyte-lineage cells
was affected by the presence of C9ORF72 mutation. Whole-
cell capacitance and input resistance measurements did not
reveal impairments in passive membrane properties versus
controls (Supporting Information Fig. 1E, 1F). The percentage
depression of rectiﬁcation indices for week 3 O41-oligoden-
drocytes in both iPSC9 lines compared with those obtained
from PDGFRa1-OPCs showed no differences compared with
control lines (iPSC91, p> 0.30; iPSC92, p> 0.27, Fig. 7G). Matu-
ration to week 3 O41-oligodendrocytes was associated with
an equivalent strong functional downregulation of IA and IK
conductances but an increase in Kir-channel expression (Sup-
porting Information Fig. 1G–1I). NaV-channel expression was
present in all PDGFRa1-OPCs (iPSC91/iPSC92, n5 5/5, N5 1/
1), but not oligodendrocytes (iPSC91/iPSC92, n5 5/4, N5 1/1).
In addition, an equivalent reduction in AMPAR unitary con-
ductance (Fig. 7H) as they mature from OPCs to oligodendro-
cytes are seen in the iPSC9 lines compared with control lines.
Collectively these ﬁndings are consistent with an absence of
maturational deﬁcit in mutant C9ORF72-derived oligodendro-
cyte-lineage cells.
DISCUSSION
Our data provide the ﬁrst functional evidence of the
maturation-dependent changes in membrane conductances that
occur in human oligodendrocytes as they differentiate from
OPCs. We demonstrate that during differentiation and matura-
tion human oligodendroglia recapitulate many of the changes in
ion channel expression observed in rodent-based systems. Using
this platform, we show that the multiple properties of mutant
C9ORF72 ALS oligodendrocyte-lineage cells, including membrane
properties and maturation, are not impaired.
Our protocol efﬁciently generates cultures containing an
enriched population of O41- and MBP1-oligodendrocytes
within 1 week of hPSC-OPC differentiation and is of an equiv-
alent duration to that recently reported [17]. The ability to
propagate OPCs with FGF2 and PDGFa treatment and the
reproducibility of the method across multiple hPSC lines con-
ﬁrms the suitability of the protocol for in vitro disease model-
ing studies. Critical to electrophysiological studies is the
observation that >80% O41-oligodendrocytes co-express
MBP, but< 10% O41-cells coexpress PDGFRa. This allows live-
staining prior to electrophysiological analysis to identify and
discriminate between OPCs and oligodendrocytes.hPSC-
derived OPCs display outwardly rectifying membrane currents
and differentiation to oligodendrocytes results in a lineariza-
tion of the membrane currents. These properties have been
widely described in rodent oligodendroglial counterparts
[23–25], in vitro mouse PSC-derived OPCs [48] and integrated
mouse PSC-derived glial restricted progenitor cells that con-
tain a proportion of OPCs [49, 50]. These data indicate that
comparable shifts in ion channel expression are occurring
throughout human oligodendrogenesis in vitro. Our data
show that the expression of voltage-gated K1 channels, IA and
IK, is prominent in OPCs in all lines and that the reduction of
expression in oligodendrocytes corresponds well to the shifts
in membrane current properties. Such data are in accordance
with previously observed developmental shifts in IA and IK
channel expression in rodent oligodendroglial cells and also
prominent expression of such membrane conductances in in
vitro mouse PSC-derived OPCs [48].
Spiking activity is observed in the majority of cells when
OPCs are depolarized and is blocked by NaV-channel blocker
TTX. However, these spikes are not classiﬁed as bone ﬁde
action potentials due to their low amplitude. Oligodendro-
cytes did not exhibit any spiking activity, and we found that
the functional expression of NaV channels to be largely
restricted to OPCs in agreement with reports from rodent oli-
godendroglial cells [24, 25, 51]. In contrast to our data, hPSC-
derived OPCs have been previously shown to exhibit regener-
ative action potential ﬁring in response to depolarization [52],
however no native TTX-sensitive current has been observed in
in vitro murine PSC-derived OPCs [48]. It is important to
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highlight that numerous reports describe native OPCs being
heterogeneous in their ability to display either spiking or
nonspiking behaviors, which are likely to represent the differ-
entiation/maturation status of the OPC rather than develop-
mentally independent subclasses of OPC [26–28, 53]. Since
OPCs in this study are examined after a period of 1 week in
oligodendrocyte differentiation medium, it may be argued
that the early processes of oligodendrocyte differentiation
may have already been initiated in OPCs leading to a reduced
expression of NaV-channels. Nonetheless the spiking activity
and NaV-channel current density data obtained from hPSC-
derived PDGFRa1-OPCs are directly comparable with popula-
tions of NG21-cells in postnatal murine gray and white
matter [26].
Our data indicate that Kir channel expression is elevated
in week 3 O41-oligodendrocytes above that seen in week 1
O41-oligodendrocytes and OPCs and correlates well with a
hyperpolarization of the RMP of week 3 O41-oligodendro-
cytes. Indeed expression of inwardly rectifying Kir4.1 subunits
in oligodendrocytes is critical to their maturation and their
ability to myelinate in vivo [29]. In addition, upregulation of
Kir4.1 subunits has been proposed to allow OPCs in the adult
brain to sense local changes in K1 concentrations generated
by neuronal activity [30].
We next investigated the ability of PDGFRa1-OPCs and
O41-oligodendrocytes to express AMPARs, GABAARs, NMDARs,
and GlyRs, each of which have previously been reported to
be expressed in oligodendrocyte-lineage cells [31]. Our data
indicate that the majority of cells respond to AMPA and GABA
and the current density of AMPARsand GABAARs decreases
with maturation of PDGFRa1-OPCs to O41-oligodendrocytes.
However, no responses to glycine or NMDA were observed in
O41-oligodendrocytes. Importantly, the maintenance condi-
tions for cultured oligodendrocyte-lineage cells have been
suggested to be a causal factor in reducing the functional
expression of both NMDARs and GlyRs [31, 54].
Given the importance of AMPARs to oligodendrocyte-lineage
cell physiology and disease [32–34], we characterized the AMPAR
composition. We initially determined that the expression of
GluA2, 3 and 4 subunit mRNA was increased relative to GluA1 in
oligodendrocytes compared with OPCs. The GluA2 subunit mRNA
was the most prominently expressed subunit in the oligodendro-
cyte. In agreement with an increase in GluA2(R) expression from
previous studies [55] (although see ref. [31]), maturation of
human oligodendrocytes is associated with a decrease in the uni-
tary conductances of AMPARs. The most parsimonious explana-
tion for this change in conductance is the increase in expression
of edited GluA2(R) subunits expressed in AMPAR complexes as
the conductance values for week 3 oligodendrocytes correspond
well to those of recombinantly expressed heteromeric GluA2(R)-
containing AMPARs [56]. In agreement with changes in unitary
AMPAR conductance estimates, we observed a reduction in inhi-
bition of AMPAR-mediated currents by NASPM, an antagonist
which blocks AMPARs that do not contain GluA2(R) subunits.
While these data indicate AMPARs predominantly expressed in
OPCs are GluA2(R)-lacking and oligodendrocytes are GluA2(R)-
containing, our data suggest that small populations of AMPARs
that possess GluA2(R)-containing subunits in OPCs and a popula-
tion of GluA2(R)-lacking AMPARs in oligodendrocytes. Consistent
with this notion is the ﬁnding that native rodent OPCs that have
been shown to express both GluA2(R)-lacking and GluA2(R)-con-
taining AMPARs, and in which their relative proportions are inﬂu-
enced in an activity-dependent manner [57]. Our data are
consistent with numerous studies reporting an increase in func-
tional expression of the GluA2(R) subunit in AMPARs expressed
in rodent oligodendrocytes upon differentiation and maturation
from OPCs [55, 58, 59]. This developmental variability in AMPAR
composition (and Ca21-permeability) is disease-relevant and con-
fers sensitivity of immature oligodendroglial cells to excitotoxic
conditions [60]. Adult human mature oligodendrocytes obtained
from white matter post mortem samples however have been
reported to express AMPARs at a low level and do not appear to
express the GluA2 subunit mRNA [34]. In this regard, AMPAR
data in this study, therefore, are in direct contrast to human
data, but are in good agreement with rodent AMPAR expression,
composition and regulation in oligodendroglial cells.
Taken together these ﬁndings show species conservation
of the deﬁning physiological properties of oligodendrocyte-
lineage cells and crucially establish a platform to investigate
disease related changes. Here, we examined the development
and maturation of mutant C9ORF72-patient derived OPCs
given the accumulating evidence implicating oligodendrocyte
dysfunction and pathology in sporadic and familial ALS includ-
ing impaired maturation of oligodendrocytes in a mSOD1
mouse model [3–5, 61]. Furthermore, the C9ORF72 hexanu-
cleotide expansion is implicated as a causal factor in abnormal
neuronal excitability [47] and recent studies indicate that
nuclear-cytoplasmic transport is affected in motorneurons [62,
63]. The precise function of C9ORF72 protein remains
unknown although accumulating evidence implicates a gain of
function mediated toxicity. This includes the absence of sur-
vival or motor deﬁcits in a C9orf72 knock-out mouse model
and a number of studies showing direct toxicity of RNA or
translated dipeptide products [62–64].
We ﬁrst conﬁrmed no difference between control and
mutant lines in respect to speciﬁcation, OPC proliferation, mat-
uration as measured by transition from PDGFRa1-OPCs to O41/
MBP1-oligodendrocytes or viability despite the widespread
presence of RNA foci. Further pathological characterization
revealed an absence of DPRs and TDP-43 and/or p62 aggregates
consistent with the recent pathological ﬁndings showing no
clear association between the presence of RNA foci and TDP-43
or p62 aggregation [65]. Further interpretation of these ﬁndings
is challenging as there is, to date, a limited literature describing
oligodendrocyte speciﬁc pathological ﬁndings in ALS. In addition
to reduced glial C9ORF72 expression compared with neurons
there is well-documented regional variation in pathology. For
instance TDP-43 and/or p62 inclusions are notably abundant in
the cerebella and hippocampi [66–68]. Together with the
absence of cytotoxicity this suggests that the presence of the
C9ORF72 mutation does not confer detrimental effects on mat-
uration or survival of oligodendrocytes.
In view of the multiple possible mechanisms of C9ORF72
mediated toxicity including non-cell autonomous effects, it
will be of interest to examine cocultures for motorneuron tox-
icity as has been shown for astrocytes [69]. Our ﬁndings are
speciﬁc to the process of oligodendrocyte-lineage cell devel-
opment and do not address myelination. In this respect, eval-
uation of mutant OPCs following transplantation into the non-
myelinating Shiverer mouse along with in vitro study of myeli-
nation upon coculture with neurons will be important. Finally,
future studies may consider the extent to which genetic
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causes of ALS are heterogeneous with respect to the proper-
ties of oligodendrocytes.
CONCLUSION
Our study demonstrates that the physiological maturation of
oligodendrocytes from OPCs derived from human pluripotent
stem cells is similar to that described for rodent models.
Electrophysiological proﬁling of oligodendrocytes from OPCs
derived from C9ORF72 patients indicates that, despite the
presence of RNA foci pathology, these cell populations display
maturation changes in intrinsic membrane properties and
AMPAR populations similar to those seen in control lines.
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